QY Research, Inc.

Global Hemostasis and Tissue Sealing Agents Sales Market Will Reach 2250 Million US$ by 2025

QYResearch is a leading market research publisher which pursuits high product quality with the belief that quality is the soul of business and consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience.


City of Industry, CA -- (SBWIRE) -- 08/22/2018 -- This report studies the global Hyperimmune Globulins market status and forecast, categorizes the global Hyperimmune Globulins market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

In the last several years, global market of Hyperimmune Globulins developed rapidly, with an average growth rate of 6%. In 2017, global revenue of Hyperimmune Globulins is nearly 1150 million USD; the actual production is about 40 million units.

The classification includes the Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Tetanus Immunoglobulins and others, and the proportion of Rabies Immunoglobulins in 2017 is about 44.2%, with the largest market share.

Hyperimmune Globulins is widely used in Government Institutions, Private Sector and Other. The most proportion of Hyperimmune Globulins is sold in Government Institutions, and the proportion in 2017 is about 62.7%.

The global Hyperimmune Globulins market is valued at 1120 million US$ in 2017 and will reach 2250 million US$ by the end of 2025, growing at a CAGR of 9.1% during 2018-2025.

The major manufacturers covered in this report

CSL Behring





Emergent (Cangene)



Hualan Bio

Shanghai RAAS

Sichuan Yuanda Shuyang

ADMA Biologics

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering

North America




Southeast Asia


We can also provide the customized separate regional or country-level reports, for the following regions:

North America

United States







South Korea




Rest of Asia-Pacific








Rest of Europe

Central & South America



Rest of South America

Middle East & Africa

Saudi Arabia


Rest of Middle East & Africa

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Hepatitis B Immunoglobulins

Rabies Immunoglobulins

Tetanus Immunoglobulins


On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

Government Institutions

Private Sector


The study objectives of this report are:

To analyze and study the global Hyperimmune Globulins sales, value, status (2013-2017) and forecast (2018-2025).

Focuses on the key Hyperimmune Globulins manufacturers, to study the sales, value, market share and development plans in future.

Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.

To define, describe and forecast the market by type, application and region.

To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends and factors driving or inhibiting the market growth.

To analyze the opportunities in the market for stakeholders by identifying the high growth segments.

To strategically analyze each submarket with respect to individual growth trend and their contribution to the market

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

Request to Buy Full Report@ https://www.qyresearch.com/settlement/pre/411b8d5417a05998c8455ecbdc6e4f74,0,1

To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Hyperimmune Globulins are as follows:

History Year: 2013-2017

Base Year: 2017

Estimated Year: 2018

Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders

Hyperimmune Globulins Manufacturers

Hyperimmune Globulins Distributors/Traders/Wholesalers

Hyperimmune Globulins Subcomponent Manufacturers

Industry Association

Downstream Vendors

Available Customizations

With the given market data, QYResearch offers customizations according to the company's specific needs. The following customization options are available for the report:

Regional and country-level analysis of the Hyperimmune Globulins market, by end-use.

Detailed analysis and profiles of additional market players.

Request Sample Copy of Report@ https://www.qyresearch.com/sample-form/form/66317/global-hyperimmune-globulins-market

About QY Research
QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert's resources (included energy automotive chemical medical ICT consumer goods etc.